- Home
- Publications
- Publication Search
- Publication Details
Title
Eribulin: A Novel Cytotoxic Chemotherapy Agent
Authors
Keywords
-
Journal
ANNALS OF PHARMACOTHERAPY
Volume 46, Issue 6, Pages 802-811
Publisher
SAGE Publications
Online
2012-05-24
DOI
10.1345/aph.1q636
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Eribulin mesylate pharmacokinetics in patients with hepatic impairment.
- (2017) P. Witteveen et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase IB study of eribulin mesylate in combination with carboplatin in patients with advanced solid tumors.
- (2017) U. Swami et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II study of eribulin (E7389) in patients (pts) with advanced urothelial cancer (UC)—Final report: A California Cancer Consortium-led NCI/CTEP-sponsored trial.
- (2017) D. I. Quinn et al. JOURNAL OF CLINICAL ONCOLOGY
- Activity of eribulin mesylate (E7389) in patients with soft tissue sarcoma (STS): Phase II studies of the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group (EORTC 62052).
- (2017) P. Schoffski et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of eribulin in Japanese patients (pts) with advanced breast cancer.
- (2017) H. Iwata et al. JOURNAL OF CLINICAL ONCOLOGY
- The relationship between age and survival outcomes for eribulin in metastatic breast cancer.
- (2017) C. Twelves et al. JOURNAL OF CLINICAL ONCOLOGY
- Eribulin dosing in patients with advanced solid tumors and hepatic impairment.
- (2017) L. A. Devriese et al. JOURNAL OF CLINICAL ONCOLOGY
- Eribulin mesylate (halichondrin B analog E7389) in platinum-sensitive ovarian cancer: A phase II study, CTEP #7431.
- (2017) M. L. Hensley et al. JOURNAL OF CLINICAL ONCOLOGY
- P5-19-02: Comparison of the Incidence of Peripheral Neuropathy with Eribulin Mesylate Versus Ixabepilone in Metastatic Breast Cancer Patients: A Randomized Phase II Study.
- (2012) L Vahdat et al. CANCER RESEARCH
- Phase II study of eribulin mesylate (E7389) in patients with metastatic castration-resistant prostate cancer stratified by prior taxane therapy
- (2011) J. S. de Bono et al. ANNALS OF ONCOLOGY
- Novel second generation analogs of eribulin. Part III: Blood–brain barrier permeability and in vivo activity in a brain tumor model
- (2011) Sridhar Narayan et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Novel second generation analogs of eribulin. Part I: Compounds containing a lipophilic C32 side chain overcome P-glycoprotein susceptibility
- (2011) Sridhar Narayan et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Comparison of Neuropathy-Inducing Effects of Eribulin Mesylate, Paclitaxel, and Ixabepilone in Mice
- (2011) K. M. Wozniak et al. CANCER RESEARCH
- Eribulin—A review of preclinical and clinical studies
- (2011) Umang Swami et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Natural product drug discovery: the successful optimization of ISP-1 and halichondrin B
- (2011) Bryan KS Yeung CURRENT OPINION IN CHEMICAL BIOLOGY
- A phase II study of the halichondrin B analog eribulin mesylate in gemcitabine refractory advanced pancreatic cancer
- (2011) Daniel J. Renouf et al. INVESTIGATIONAL NEW DRUGS
- Interactions of Halichondrin B and Eribulin with Tubulin
- (2011) Ruoli Bai et al. Journal of Chemical Information and Modeling
- Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study
- (2011) Javier Cortes et al. LANCET
- Phase II Study of the Halichondrin B Analog Eribulin Mesylate in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With an Anthracycline, a Taxane, and Capecitabine
- (2010) Javier Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- The Place for Eribulin in the Treatment of Metastatic Breast Cancer
- (2010) William J. Gradishar Current Oncology Reports
- Eribulin Binds at Microtubule Ends to a Single Site on Tubulin To Suppress Dynamic Instability
- (2009) Jennifer A. Smith et al. BIOCHEMISTRY
- A Phase I Study of Eribulin Mesylate (E7389), a Mechanistically Novel Inhibitor of Microtubule Dynamics, in Patients with Advanced Solid Malignancies
- (2009) S. Goel et al. CLINICAL CANCER RESEARCH
- Phase I Study of Eribulin Mesylate Administered Once Every 21 Days in Patients with Advanced Solid Tumors
- (2009) A. R. Tan et al. CLINICAL CANCER RESEARCH
- Phase II evaluation of eribulin mesylate (E7389, NSC 707389) in patients with metastatic or recurrent squamous cell carcinoma of the head and neck: Southwest Oncology Group trial S0618
- (2009) Susanne M. Arnold et al. INVESTIGATIONAL NEW DRUGS
- Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
- (2009) Linda T. Vahdat et al. JOURNAL OF CLINICAL ONCOLOGY
- Tubulin-Interactive Natural Products as Anticancer Agents(1)
- (2009) David G. I. Kingston JOURNAL OF NATURAL PRODUCTS
- Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4
- (2008) Z.-Y. Zhang et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: Use of Chemotherapy and Radiation Therapy Protectants
- (2008) Martee L. Hensley et al. JOURNAL OF CLINICAL ONCOLOGY
- Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase
- (2008) T. Okouneva et al. MOLECULAR CANCER THERAPEUTICS
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started